Last Price
1.81
Today's Change
+0.02 (1.11%)
Day's Change
1.79 - 1.88
Trading Volume
255,542
Market Cap
8 Million
Shares Outstanding
4 Million
Avg Volume
6,560,208
Avg Price (50 Days)
2.36
Avg Price (200 Days)
3.77
PE Ratio
-0.19
EPS
-9.75
Earnings Announcement
31-Mar-2025
Previous Close
1.79
Open
1.83
Day's Range
1.79 - 1.88
Year Range
1.53 - 10.35
Trading Volume
257,846
1 Day Change
1.12%
5 Day Change
-5.73%
1 Month Change
-37.80%
3 Month Change
-18.10%
6 Month Change
-39.26%
Ytd Change
-4.74%
1 Year Change
-69.53%
3 Year Change
-98.14%
5 Year Change
-99.48%
10 Year Change
-100.00%
Max Change
-99.43%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.